Millennium Management’s Nektar Therapeutics NKTR Stock Holding History

Millennium Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,000	Closed	-$1.42M	–	6313
2025 Q3	$1.42M	Sell	25,000 -54,000	-68%	-$1.79M	﹤0.01%	4341
2025 Q2	$2.04M	Buy	+79,000	New	+$887K	﹤0.01%	3859
2022 Q2	–	Sell	-52,773	Closed	-$4.27M	–	7317
2022 Q1	$4.27M	Buy	52,773 +32,146	+156%	+$4.76M	﹤0.01%	3105
2021 Q4	$4.18M	Buy	+20,627	New	+$4.47M	﹤0.01%	3091
2021 Q1	–	Sell	-6,667	Closed	-$1.7M	–	6329
2020 Q4	$1.7M	Buy	+6,667	New	+$1.72M	﹤0.01%	3369
2018 Q4	–	Sell	-5,000	Closed	-$4.57M	–	4043
2018 Q3	$4.57M	Buy	+5,000	New	+$4.27M	0.01%	1873
2018 Q1	–	Sell	-2,200	Closed	-$1.97M	–	3936
2017 Q4	$1.97M	Buy	+2,200	New	+$1.3M	﹤0.01%	2296
2017 Q2	–	Sell	-13,333	Closed	-$4.69M	–	3725
2017 Q1	$4.69M	Buy	+13,333	New	+$3M	0.01%	1491
2013 Q4	–	Sell	-70,040	Closed	-$11M	–	3665
2013 Q3	$11M	Buy	70,040 +29,887	+74%	+$5.53M	0.04%	632
2013 Q2	$6.96M	Buy	+40,153	New	+$6.16M	0.02%	826

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management's NKTR Position: Q1 2026 in Review

Millennium Management reduced its Nektar Therapeutics (NKTR) stake by 11% in Q1 2026, selling an estimated $2.84M and leaving 404,277 shares worth $29.1M. The position accounts for 0.01% of the portfolio, ranked #1259.

Millennium Management first reported a position in NKTR in Q2 2013 and has held it in 45 quarters since. The position peaked at $114M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Millennium Management held 404,277 shares of Nektar Therapeutics worth $29.1M as of Q1 2026.
Millennium Management sold 49,798 Nektar Therapeutics shares in Q1 2026, an estimated $2.84M.
Nektar Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1259 holding.
Millennium Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 45 quarters since.
Millennium Management's Nektar Therapeutics position peaked at $114M in Q1 2018.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.